Skip to main content

Table 3 The Performances of the Three Predictive Models

From: 18F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma

Models

AUC (95%CI)

ACC (95%CI)

SEN (95%CI)

SPE (95%CI)

PPV (95%CI)

NPV (95% CI)

Radiomics model

 Primary cohort

0.94 (0.93, 0.96)

91.3% (89.8, 93.3)

94.9% (93.1, 96.6)

87.5% (84.4, 90.7)

90.2% (87.8, 92.8)

93.3% (91.1, 95.6)

 Validation cohort

0.86 (0.83, 0.88)

77.8% (75.2, 80.3)

75.0% (71.5, 78.6)

81.3% (77.5, 84.9)

83.3% (80.0, 86.7)

72.2% (68.2, 76.1)

Clinical model

 Primary cohort

0.64 (0.61, 0.67)

64.8% (61.9, 67.9)

71.8% (68.1, 75.7)

56.3% (51.6, 61.1)

66.7% (62.9, 70.6)

62.1% (57.3, 67.2)

 Validation cohort

0.69 (0.66, 0.72)

66.4% (66.6, 72.3)

75.0% (71.3, 78.5)

62.5% (58.1, 67.0)

71.4% (67.9, 75.1)

66.7% (61.9, 71.1)

Fusion model

 Primary cohort

0.85 (0.83, 0.87)

64.8% (62.0, 67.7)

71.8% (68.1, 75.5)

56.3% (51.6, 60.9)

66.7% (63.0, 70.4)

62.1% (57.5, 66.7)

 Validation cohort

0.85 (0.82, 0.87)

72.7% (78.1, 82.9)

80.0% (76.6, 83.5)

62.5% (58.0, 67.0)

72.7% (69.3, 76.3)

71.4% (66.7, 76.1)

  1. Abbreviations: CI Confidence interval, AUC Area under receiver-operating characteristic curve, ACC Accuracy, SEN Sensitivity, SPE Specificity, PPV Positive predictive value, NPV Negative predictive value